Mast cells have been shown to be potentially critical coordinators of the initial phase of the antitumor immune response in cancer therapy, capable of treating cancer through mast cell stabilizers, mast cell mediator modulators, anti-targeting inhibitory receptors and ligands, FεR1 signal pathway activators/inhibitors, TLR activators and c-KIT inhibitors (150). The gene discussed is KIT; the disease is cancer.